131 Participants Needed

Autogene Cevumeran + Pembrolizumab for Melanoma

(IMCODE001 Trial)

Recruiting at 76 trial locations
RS
RS
Overseen ByReference Study ID Number: IMCODE001(GO40558) https://forpatients.roche.com/
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Genentech, Inc.
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Breakthrough TherapyThis drug has been fast-tracked for approval by the FDA given its high promise

Trial Summary

What is the purpose of this trial?

This study will evaluate the efficacy, safety, pharmacokinetics, and patient-reported outcomes (PROs) of autogene cevumeran (RO7198457) plus pembrolizumab compared with pembrolizumab alone in patients with previously untreated advanced melanoma.

Research Team

CT

Clinical Trials

Principal Investigator

Hoffmann-La Roche

Eligibility Criteria

This trial is for adults with advanced melanoma that hasn't been treated before. They should have a certain level of physical fitness (ECOG 0 or 1), a life expectancy of at least 12 weeks, and their major organs must be functioning well. People can't join if they've had organ transplants, significant heart disease, liver problems, eye melanoma, untreated brain metastases, autoimmune diseases, HIV/AIDS, hepatitis B or C.

Inclusion Criteria

Your disease can be measured using a specific method called RECIST v1.1.
I have advanced melanoma and haven't received systemic anti-cancer treatments, with some exceptions.
My blood and organs are functioning well.
See 4 more

Exclusion Criteria

I have had my spleen removed.
I have active hepatitis B, C, or tuberculosis.
I have not had any cancer treatment except those allowed in the study.
See 7 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Safety Run-in

Participants receive at least one cycle of 200 mg pembrolizumab monotherapy by IV infusion followed by 200 mg pembrolizumab IV infusion every 3 weeks plus a recommended dose of autogene cevumeran

6 weeks
2 visits (in-person)

Randomized Treatment

Participants receive either pembrolizumab alone or in combination with autogene cevumeran, with the option to cross over to combination treatment after confirmed disease progression

24 months
8 visits (in-person) every 3 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Pembrolizumab
  • RO7198457
Trial Overview The study is testing the combination of Autogene cevumeran (RO7198457) with Pembrolizumab versus using Pembrolizumab alone in patients who haven't received treatment for their advanced melanoma. It aims to see which approach works better and how safe it is.
Participant Groups
3Treatment groups
Experimental Treatment
Active Control
Group I: Safety Run-in Period: Autogene Cevumeran + PembrolizumabExperimental Treatment2 Interventions
Participants will receive at least one cycle of 200 mg pembrolizumab monotherapy by intravenous (IV) infusion followed by 200 mg pembrolizumab IV infusion every 3 weeks (Q3W) plus a recommended dose of autogene cevumeran.
Group II: Randomized Period: Arm B: Autogene Cevumeran + PembrolizumabExperimental Treatment2 Interventions
Participants will receive at least one cycle of 200 mg pembrolizumab monotherapy by IV infusion followed by 200 mg pembrolizumab IV infusion Q3W plus a recommended dose of autogene cevumeran.
Group III: Randomized Period: Arm A: PembrolizumabActive Control1 Intervention
Participants will receive 200 mg pembrolizumab administered by IV infusion Q3W. Participants in Arm A have the option to cross over to combination treatment with autogene cevumeran plus pembrolizumab (Arm B) after confirmed disease progression.

Pembrolizumab is already approved in United States, European Union, United Kingdom for the following indications:

🇺🇸
Approved in United States as KEYTRUDA for:
  • Head and neck squamous cell carcinoma (HNSCC) with PD-L1 CPS ≥1
  • Melanoma
  • Non-small cell lung cancer (NSCLC)
  • Urothelial carcinoma
  • Colorectal cancer
  • Gastric cancer
  • Hepatocellular carcinoma
  • Renal cell carcinoma
  • Cervical cancer
  • Endometrial carcinoma
🇪🇺
Approved in European Union as KEYTRUDA for:
  • Head and neck squamous cell carcinoma (HNSCC) with PD-L1 CPS ≥1
  • Melanoma
  • Non-small cell lung cancer (NSCLC)
  • Urothelial carcinoma
  • Colorectal cancer
  • Gastric cancer
  • Hepatocellular carcinoma
  • Renal cell carcinoma
  • Cervical cancer
  • Endometrial carcinoma
🇬🇧
Approved in United Kingdom as KEYTRUDA for:
  • Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) with PD-L1 CPS ≥1

Find a Clinic Near You

Who Is Running the Clinical Trial?

Genentech, Inc.

Lead Sponsor

Trials
1,578
Recruited
569,000+
Ashley Magargee profile image

Ashley Magargee

Genentech, Inc.

Chief Executive Officer since 2024

MBA from Harvard University, BA from Princeton University

Levi Garraway profile image

Levi Garraway

Genentech, Inc.

Chief Medical Officer since 2021

MD, PhD

BioNTech SE

Industry Sponsor

Trials
84
Recruited
120,000+

Prof. Dr. Ugur Sahin

BioNTech SE

Chief Executive Officer since 2008

MD from University of Cologne

Prof. Özlem Türeci

BioNTech SE

Chief Medical Officer since 2018

MD from Saarland University

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security